OSR Holdings, Inc. (NASDAQ:OSRH) today announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM Europe AG for the global licensing of its lead oncology asset VXM01. The revised structure is designed to improve capital efficiency and shift economic benefits directly to the parent company, OSR Holdings and its shareholders.

Under the new framework, OSR Holdings will become a direct counterparty to the licensing agreement alongside its Swiss subsidiary, Vaximm AG, and an investment vehicle sponsored by BCM Europe AG. As part of this restructuring, up to $815 million in milestone payments, excluding royalties, will be payable directly to OSR Holdings rather than at the subsidiary level, reducing reliance on upstream distributions and simplifying the flow of funds.

In parallel, OSR Holdings will provide a development financing facility of up to $30 million to Vaximm AG, which may be drawn as needed to support clinical development of VXM01. This replaces the previous structure in which upfront payments were made directly by the BCME-sponsored fund to the subsidiary. The drawdown structure allows Vaximm to access capital in line with actual clinical program needs, improving capital efficiency across the organization.

The revised structure is expected to enhance value for OSR Holdings shareholders through:

Direct parent-level value capture from milestone and royalty payments

Reduced reliance on subsidiary-level distributions, simplifying the flow of funds

Improved capital efficiency through drawdown-based development funding

Centralized control over capital allocation at the OSR Holdings level

"This revised structure enables us to capture the full economic potential of VXM01 at the OSR Holdings level while funding its development in a disciplined, capital-efficient way," said Peter Hwang, CEO of OSR Holdings. "We believe it positions us to translate clinical progress more directly into shareholder value, which is critical as we advance VXM01 into later-stage development."

OSR Holdings also retains an option to issue up to $15 million of common stock to the BCME fund at $10 per share, exercisable six months after execution of the definitive agreement at OSR Holdings' sole discretion. The stated issuance price, set above recent trading levels, reflects alignment around the long-term value potential of VXM01 and provides additional financing flexibility while maintaining control over timing and potential dilution.

Provisions for digital asset financing, which had been contemplated in the prior term sheet, have been deferred by mutual agreement pending further regulatory clarity applicable to public companies holding and transacting in digital assets. The Parties reserve the right to reintroduce such provisions in a future amendment once the regulatory environment is sufficiently defined.

The April 30, 2026 target date for execution of a definitive agreement remains unchanged, subject to board approval and an independent fairness opinion. VXM01 is an oral DNA-based immunotherapy targeting VEGFR-2 and is positioned for late-stage clinical development in oncology.

Key Takeaways

Direct value capture: Milestones and royalties payable directly to OSRH

Total deal size: Up to $815M in milestones, excluding royalties

Upfront restructured: $30M development facility to Vaximm, drawable as needed

Equity option: $15M at $10/share, exercisable 6 months after execution at OSRH's sole discretion

Digital assets: Deferred pending regulatory clarity for public companies

Target signing: Definitive agreement expected by April 30, 2026